Discovered via structure-guided drug design, MS351 inhibits CBX7 binding to H3K27me3 when it is bound to RNA. It also derepresses CBX7 target genes in both mouse embryonic stem cells and PC3 prostate cancer cells. Here, CBX7 is linked to prostate carcinoma.